Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.

ABSTRACT:

Importance

Melanoma treatment has been revolutionized with the development of immune-based therapies that offer durable clinical responses in a subset of patients. Clinical outcomes after treatment by immunotherapy can be influenced by the host's immune system. The immune system is modified with age by age-related immune dysfunction.

Objective

To evaluate if age influences clinical outcome and immune adverse events in patients treated by immunotherapy for metastatic melanoma.

Design, setting, and participants

This was a single-center cohort analysis in patients treated with immunotherapy for metastatic melanoma between January 2007 and February 2016, in the Lyon Sud Hospital, France. A total of 92 patients with metastatic melanoma treated with ipilimumab, nivolumab, o

SUBMITTER: Perier-Muzet M 

PROVIDER: S-EPMC5833580 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature